8-K: Viking Therapeutics Announces Positive Financial Results and Clinical Pipeline Progress

Viking Therapeutics reports strong year-end cash position of $903 million and plans to initiate Phase 3 studies for subcutaneous VK2735 for obesity in 2Q25.

Summary

• Viking Therapeutics announced its financial results for the fourth quarter and year ended December 31, 2024, along with a corporate update.
• The company's cash position at year-end was strong, with $903 million in cash and equivalents.
• Viking plans to initiate Phase 3 studies for subcutaneous VK2735 for obesity in the second quarter of 2025.
• A Phase 2 VENTURE-Oral Dosing trial evaluating VK2735 in obesity is currently underway, with data expected in the second half of 2025.
• The company highlighted best-in-class data from the Phase 2b VOYAGE trial in MASH, presented at The Liver Meeting 2024.
• A Phase 1b study evaluating VK0214 in X-ALD demonstrated improvement in a key biomarker.
• Viking is also progressing its Dual Amylin and Calcitonin Receptor Agonist (DACRA) program, with an IND planned for 2025.
• Research and development expenses were $31.0 million for the three months ended December 31, 2024, compared to $20.5 million for the same period in 2023.
• General and administrative expenses were $15.3 million for the three months ended December 31, 2024, compared to $8.8 million for the same period in 2023.
• For the three months ended December 31, 2024, Viking reported a net loss of $35.4 million, or $0.32 per share, compared to a net loss of $24.6 million, or $0.25 per share, in the corresponding period in 2023.
• Research and development expenses for the year ended December 31, 2024, were $101.6 million compared to $63.8 million for the same period in 2023.
• General and administrative expenses for the year ended December 31, 2024, were $49.3 million compared to $37.0 million for the same period in 2023.
• For the year ended December 31, 2024, Viking reported a net loss of $110.0 million, or $1.01 per share, compared to a net loss of $85.9 million, or $0.91 per share, in the corresponding period in 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, a robust cash position, and clear plans for future development; while there are reported net losses, the overall tone is optimistic due to the promising pipeline and financial stability.

Positives

• Viking has a strong cash position of $903 million, providing resources for clinical development.
• VK2735 demonstrated significant weight loss in both subcutaneous and oral formulations.
• VK2809 showed promising results in MASH resolution and fibrosis improvement.
• VK0214 demonstrated improvement in key biomarkers for X-ALD.
• The company is advancing its DACRA program with plans to file an IND application in 2025.

Negatives

• Viking reported a net loss of $35.4 million for the three months ended December 31, 2024.
• Viking reported a net loss of $110.0 million for the year ended December 31, 2024.
• Research and development expenses and general and administrative expenses increased compared to the same periods in the previous year.

Risks

• The success, cost, and timing of Viking's product candidate development activities and clinical trials are subject to risks and uncertainties.
• Prior clinical and preclinical results may not be replicated.
• Regulatory requirements pose risks to the development and approval of Viking's product candidates.

Future Outlook

Viking expects to initiate Phase 3 trials evaluating subcutaneous VK2735 in obesity in 2Q25 and anticipates reporting data from the Phase 2 VENTURE-Oral Dosing trial in 2H25; the company also plans to file an IND application for its DACRA program later in 2025.

Management Comments

• Brian Lian, Ph.D., chief executive officer of Viking, stated that 2024 was an exciting and productive year for Viking.
• Brian Lian, Ph.D., stated that each study successfully achieved their objectives, with each in our view demonstrating best-in-class data.

Industry Context

Viking's focus on metabolic and endocrine disorders, particularly obesity and MASH, aligns with significant unmet medical needs and growing market opportunities; the company's pipeline programs, including VK2735 and VK2809, are targeting competitive areas with potential for best-in-class therapies.

Comparison to Industry Standards

• The reported weight loss of up to 14.7% with subcutaneous VK2735 in the Phase 2 VENTURE study is competitive with other GLP-1/GIP agonists in development, such as Eli Lilly's tirzepatide (Mounjaro) which has shown similar levels of weight reduction.
• The MASH resolution rates of 63% to 75% observed with VK2809 in the VOYAGE study compare favorably to other therapies in development for MASH, such as Madrigal Pharmaceuticals' resmetirom, which has shown resolution rates in the 25-30% range in Phase 3 trials.
• The 38% reduction in VLCFA levels with VK0214 in X-ALD patients suggests a potential therapeutic benefit in a disease with limited treatment options, positioning it as a potential competitor to gene therapy approaches or hematopoietic stem cell transplantation.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial position and promising clinical trial results.
• Employees: Positive impact due to company growth and advancement of pipeline programs.
• Patients: Potential positive impact due to the development of novel therapies for metabolic and endocrine disorders.

Next Steps

• Initiate Phase 3 studies for subcutaneous VK2735 for obesity in 2Q25.
• Report data from Phase 2 VENTURE-Oral Dosing trial evaluating VK2735 in obesity in 2H25.
• File an IND application for the Dual Amylin and Calcitonin Receptor Agonist (DACRA) program in 2025.
• Explore partnering opportunities for the further development of VK0214.
• Participate in upcoming investor events.

Key Dates